Olav Engebråten
Position: MD, 1. aman, Dr. med
Phone: +47 22 78 18 62
Email:
 

Author network for Olav Engebråten by COREMINE medical


Publications 2017

Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
Dynamic 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
Mol Imaging Biol, 19 (2), 271-279
PubMed 27541026

Publications 2016

Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA (2016)
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
BMC Cancer, 16, 191
PubMed 26951085

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE (2016)
Fatigue During and After Breast Cancer Therapy-A Prospective Study
J Pain Symptom Manage, 53 (3), 551-560
PubMed 28042070

Publications 2015

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
PubMed 26554649

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C (2015)
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Genes Dev, 29 (12), 1298-315
PubMed 26080815

Publications 2014

Bagherifam S, Skjeldal FM, Griffiths G, Mælandsmo GM, Engebråten O, Nyström B, Hasirci V, Hasirci N (2014)
pH-responsive nano carriers for doxorubicin delivery
Pharm Res, 32 (4), 1249-63
PubMed 25288014

Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebråten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A (2014)
In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
J Magn Reson Imaging, 41 (3), 601-9
PubMed 24532410

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
Breast Cancer Res, 16 (1), R5
PubMed 24447408

Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E (2014)
Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
Acta Oncol, 53 (8), 1086-92
PubMed 25017377

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T (2014)
Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
J Magn Reson Imaging, 40 (6), 1382-91
PubMed 24470360

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
PubMed 25419568

Publications 2013

Engebraaten O, Vollan HK, Børresen-Dale AL (2013)
Triple-negative breast cancer and the need for new therapeutic targets
Am J Pathol, 183 (4), 1064-74
PubMed 23920327

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA (2013)
Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
Magn Reson Med, 71 (6), 1973-81
PubMed 23878023

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
Nucl Med Mol Imaging, 47 (3), 173-80
PubMed 24900104

Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
Acta Oncol, 52 (7), 1566-72
PubMed 23984812

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
Clin Cancer Res, 20 (2), 404-12
PubMed 24192926

Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G (2013)
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Breast Cancer Res, 15 (1), R16
PubMed 23448424

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS (2013)
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
J Magn Reson Imaging, 38 (5), 1043-53
PubMed 23908122

Publications 2012

Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T (2012)
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Mol Oncol, 7 (1), 130-42
PubMed 23142657

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
ISRN Oncol, 2012, 176789
PubMed 22666610

Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
PLoS One, 7 (9), e45492
PubMed 23029050

Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O (2012)
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
Mol Oncol, 6 (4), 418-27
PubMed 22521242

Publications 2011

Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
PubMed 21508672

Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS (2011)
13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns
NMR Biomed, 24 (10), 1243-52
PubMed 21462378

Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS (2011)
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
J Magn Reson Imaging, 35 (5), 1098-107
PubMed 22170753

Moestue SA, Engebraaten O, Gribbestad IS (2011)
Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy
Mol Oncol, 5 (3), 224-41
PubMed 21536506

Publications 2010

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T (2010)
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
Eur Radiol, 21 (6), 1188-99
PubMed 21127880

Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS (2010)
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
BMC Cancer, 10, 433
PubMed 20716336

Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
Pigment Cell Melanoma Res, 23 (3), 449-51
PubMed 20236249

Publications 2009

Andersson Y, Engebraaten O, Fodstad Ø (2009)
Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
Br J Cancer, 101 (8), 1307-15
PubMed 19773757

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
PubMed 19713161

Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad Ø (2009)
Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins
Anticancer Res, 29 (1), 131-7
PubMed 19331142

Publications 2007

Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O (2007)
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
J Gene Med, 9 (6), 440-51
PubMed 17410615

Publications 2006

Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM (2006)
Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines
Cancer Biol Ther, 5 (11), 1511-20
PubMed 17012835

Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM (2006)
Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
J Gene Med, 8 (6), 707-18
PubMed 16518880

Publications 2005

Engesaeter BØ, Bonsted A, Berg K, Høgset A, Engebråten O, Fodstad Ø, Curiel DT, Maelandsmo GM (2005)
PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
Cancer Gene Ther, 12 (5), 439-48
PubMed 15678152

Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O (2005)
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
Cancer Gene Ther, 12 (11), 864-72
PubMed 15891771

Publications 2004

Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, Engebraaten O (2004)
Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
J Neurosurg, 100 (2), 320-7
PubMed 15086240

Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad Ø, Engebraaten O (2004)
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
Exp Cell Res, 294 (1), 130-9
PubMed 14980508

Publications 2003

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O (2003)
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
PubMed 12856717

Publications 2002

Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002)
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
PubMed 11857366

Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002)
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102

Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraaten O (2002)
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model
Acta Neuropathol, 105 (1), 49-57
PubMed 12471461

Ree AH, Engebraaten O, Hovig E, Fodstad Ø (2002)
Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
Int J Cancer, 97 (1), 28-33
PubMed 11774240

Publications 2001

Laerum OD, Nygaar SJ, Steine S, Mørk SJ, Engebraaten O, Peraud A, Kleihues P, Ohgaki H (2001)
Invasiveness in vitro and biological markers in human primary glioblastomas
J Neurooncol, 54 (1), 1-8
PubMed 11763417

Publications 2000

Engebraaten O, Sivam G, Juell S, Fodstad O (2000)
Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats
Int J Cancer, 88 (6), 970-6
PubMed 11093823

Visted T, Thorsen J, Thorsen F, Read TA, Ulvestad E, Engebraaten O, Sorensen D, Ylä-Herttuala S, Tyynela K, Rucklidge G, Edvardsen K, Bjerkvig R, Lund-Johansen M (2000)
lacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS
Int J Cancer, 85 (2), 228-35
PubMed 10629082

Publications 1999

Engebraaten O, Fodstad O (1999)
Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats
Int J Cancer, 82 (2), 219-25
PubMed 10389756

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999)
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
PubMed 10413165

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
Expression of a novel factor in human breast cancer cells with metastatic potential
Cancer Res, 59 (18), 4675-80
PubMed 10493524

Publications 1998

Wyller TB, Engebråten O (1998)
[Use of antipsychotic drugs in a long-term care institution. Experiences with implementing clinical guidelines]
Tidsskr Nor Laegeforen, 118 (14), 2144-7
PubMed 9656807

Publications 1997

Mahesparan R, Tysnes BB, Edvardsen K, Haugeland HK, Cabrera IG, Lund-Johansen M, Engebraaten O, Bjerkvig R (1997)
Role of high molecular weight extracellular matrix proteins in glioma cell migration
Neuropathol Appl Neurobiol, 23 (2), 102-12
PubMed 9160895

Publications 1996

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
PubMed 8611425

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106

Publications 1995

Engebråten O, Kallevåg T, Sørbø HB, Bjugn R (1995)
[Emergency hospital admissions. A survey and consumer assessment of conditions in an emergency department admission office]
Tidsskr Nor Laegeforen, 115 (23), 2917-20
PubMed 7570518

Engebråten O, Sørbø HB, Kallevåg T, Bjugn R (1995)
[Primary health care and emergency admission of patients. What happened prior to admissions and how did the patients experience the primary health care system?]
Tidsskr Nor Laegeforen, 115 (23), 2913-6
PubMed 7570517

Publications 1992

Lehmann AK, Bjugn R, Engebråten O, Hexeberg E (1992)
[Working conditions of medical students--medical students and research]
Tidsskr Nor Laegeforen, 112 (17), 2202-4
PubMed 1523657

Lehmann AK, Hexeberg E, Engebråten O, Bjugn R (1992)
[Research interest and recruitment potential--medical students and research]
Tidsskr Nor Laegeforen, 112 (17), 2205-7
PubMed 1523658